Substituent effect of side chains on the photochemical behavior of a new generation 1,4-dihydropyridine: Lercanidipine (cas 100427-26-7)
-
Add time:07/30/2019 Source:sciencedirect.com
Lercanidipine (LERCA) is a third generation antihypertensive drug belonging to the 1,4-dihydropyridine’s family, which has been reported to induce photoallergic and/or phototoxic effects in patients with long term treatment. The electronic nature of substituents on the 4-aryl moiety bonded to the 1,4-dihydropyridine ring has been described to strongly affect the photophysical and photochemical behavior of this family of compounds, which displays a typical absorption band around 360 nm. LERCA undergoes photodegradation after excitation, with a first order kinetic, in significant competition to the radiative path. The photodegradation quantum yields for LERCA are higher than for its homologue nimodipine (NIMO), thus indicating that the substituents on the 1,4-dihydropyridinic ring also affect their photophysical and photochemical properties. The media where the photodegradation takes place impacts on the product profile, in a homogeneous one the photoproducts obtained appear to be more polar than those obtained for a micro-heterogeneous one (micelles or bilayers mimicking biological media).
We also recommend Trading Suppliers and Manufacturers of Lercanidipine (cas 100427-26-7). Pls Click Website Link as below: cas 100427-26-7 suppliers
Prev:Neuroprotective effect of Lercanidipine (cas 100427-26-7) in middle cerebral artery occlusion model of stroke in rats
Next:Evaluation of the Efficacy and Safety of the Lercanidipine (cas 100427-26-7)/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine (cas 100427-26-7) Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Evaluation of the Efficacy and Safety of the Lercanidipine (cas 100427-26-7)/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine (cas 100427-26-7) Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial07/31/2019
- Neuroprotective effect of Lercanidipine (cas 100427-26-7) in middle cerebral artery occlusion model of stroke in rats07/29/2019
- Dissolution and bioavailability of Lercanidipine (cas 100427-26-7)–hydroxypropylmethyl cellulose nanoparticles with surfactant07/28/2019
-
Health and Chemical more >
-
Related Products


